CASE DESCRIPTION
================

A 59-year-old woman presented with a 5-week history of obstructive jaundice (dark urine, pale stools and itching). She had type 2 diabetes mellitus with peripheral neuropathy and nephropathy, hypertension, polymyalgia and chronic fatigue. She had no previous or family history of liver problems.

She had started lisinopril for diabetic nephropathy (creatinine 130 μmol/l (N 44--80 μmol/l) with albuminuria) 8 weeks previously. After 3 weeks, she reported icteric eyes and skin to her general practitioner who stopped the lisinopril. She denied excessive alcohol intake and over-the-counter drug use. Her long-term repeat medications were betahistine, metformin, paroxetine, prochlorperazine, atorvastatin and gliclazide. No other prescribed medication had been started during the previous year.

On examination, the patient was alert, had a high body mass index (108 kg) and was jaundiced, without other stigmata of liver disease, and the abdomen was normal. Tests showed initial serum bilirubin 93 μmol/l (N \<21 μmol/l), alanine transaminase (ALT) 92 IU/l (N \<33 IU/l), alkaline phosphatase (ALP) 1,916 IU/l (N 30--130 IU/l), prothrombin time (PT) 30 seconds (N 9.4--11.4 seconds), corrected from 30 to 12.8 seconds after vitamin K administration, white cell count 10.5×10^9^/l (N 3.5--9.5×10^9^/l), eosinophils 0.22×10^9^/l (N 0.04--0.5×109/l) and creatinine 105 μmol/l. Her liver function tests (LFT), before the initiation of the lisinopril, were within the normal ranges. Serum was negative for hepatitis A, B, C, E, EBV, CMV and HIV markers and also for antinuclear, smooth muscle, and liver kidney microsomal and mitochondrial antibodies. Serum IgA was mildly elevated at 4.9 g/l (N 0.8--4.0 g/l), while serum IgG, IgM, alpha-1-antitrypsin, ferritin and serum iron were all within normal ranges. Ultrasound of the abdomen showed fatty infiltration of the liver with a normal biliary tree. Magnetic resonance cholangiopancreatography confirmed no intra- or extrahepatic biliary dilatation.

A liver biopsy was performed 7 days after admission ([Figs. 1](#f1-1600-1-12698-1-10-20200414){ref-type="fig"} and [2](#f2-1600-1-12698-1-10-20200414){ref-type="fig"}). The peri-portal areas showed cholestasis with canalicular bile plugs, which was acute as no copper or copper-binding protein was seen ([Fig. 2](#f2-1600-1-12698-1-10-20200414){ref-type="fig"}), and fibrosis, with focal portal-to-portal bridging fibrosis ([Fig. 1](#f1-1600-1-12698-1-10-20200414){ref-type="fig"}) was also present. There was also minimal centrilobular steatosis. The findings were consistent with drug-induced liver injury (DILI). Fatty liver disease was not demonstrated on this liver biopsy.

Contrast computed tomography (CT) was performed to rule out any serious internal pathology as the patient had been referred for consideration for liver transplantation. Despite appropriate pre- and post-CT scan precautions, she developed contrast nephropathy (creatinine rising to 335 μmol/l) and needed dialysis for 4 weeks. She also developed influenza A which was treated with oseltamivir.

Although the lisinopril had been stopped 5 weeks before admission, LFT initially worsened with bilirubin rising to 270 μmol/l, PT was 12.6 seconds, and ALT, AST, ALP and GGT were all elevated. The patient was referred to the regional liver transplant centre, but was deemed unsuitable for transplantation as she was so unwell with a poor baseline functional status.

Subsequently, LFT improved modestly (ALP 963 IU/l). After 3 months in hospital, the patient was discharged to a rehabilitation centre to improve her fitness for liver transplantation. The jaundice persisted (bilirubin hovering between 170 and 200 μmol/l), with ALP and GGT remaining elevated. When seen in the clinic 4 weeks after discharge, the patient had deteriorated and was unable to engage with rehabilitation. She became completely bed bound and died shortly afterwards.

DISCUSSION AND LITERATURE REVIEW
================================

ACE-I are frequently used in patients with hypertension, diabetic nephropathy and after myocardial infarction^\[[@b1-1600-1-12698-1-10-20200414]\]^. Severe side effects associated with ACE-I are uncommon. The reported case showed a rare pattern of ACE-I-induced liver injury.

DILI is usually a diagnosis of exclusion. Improvement in LFT after stopping the drug is typical but not invariable. Biochemically, DILI can be of one of three types: hepatocellular, cholestatic or mixed pattern. The type is determined by the equation: Ratio (R)=ALT (measured in multiples of upper limit of normal)/ALP (measured in multiples of upper limit of normal). DILI is considered hepatocellular if R is more than 5, cholestatic if R is less than 2 and mixed if R is between 2 and 5^\[[@b2-1600-1-12698-1-10-20200414]\]^.

Cholestatic liver injury has been reported with several other ACE-I, including enalapril, ramipril and fosinopril^\[[@b3-1600-1-12698-1-10-20200414]\]^. A PubMed and Medline search yielded only six other reported cases of lisinopril-induced liver injury ^\[[@b1-1600-1-12698-1-10-20200414],\ [@b4-1600-1-12698-1-10-20200414]--[@b8-1600-1-12698-1-10-20200414]\]^. Of these, five showed hepatocellular damage and one showed cholestatic injury^\[[@b1-1600-1-12698-1-10-20200414]\]^. No patient had peripheral eosinophilia which is generally associated with hypersensitivity reactions^\[[@b8-1600-1-12698-1-10-20200414]\]^.

[Table 1](#t1-1600-1-12698-1-10-20200414){ref-type="table"}. provides details of the present and previously published cases of lisinopril-induced liver injury.

Liver histology was available in five patients. All, including the present case, developed lymphocytic or monocytic portal or peri-portal hepatitis^\[[@b1-1600-1-12698-1-10-20200414],\ [@b4-1600-1-12698-1-10-20200414],\ [@b7-1600-1-12698-1-10-20200414],\ [@b8-1600-1-12698-1-10-20200414]\]^. Histological cholestasis was present in four cases^\[[@b1-1600-1-12698-1-10-20200414],\ [@b4-1600-1-12698-1-10-20200414],\ [@b7-1600-1-12698-1-10-20200414]\]^ and three cases showed evidence of portal fibrosis ^\[[@b1-1600-1-12698-1-10-20200414],\ [@b7-1600-1-12698-1-10-20200414]\]^. Centrilobular necrosis was seen in one case only \[[@b4-1600-1-12698-1-10-20200414]\]. None of the patients had eosinophilic infiltration.

In three patients, the liver injury resolved. Three other patients (including the one reported here) died and one developed chronic liver disease ^\[[@b1-1600-1-12698-1-10-20200414],\ [@b4-1600-1-12698-1-10-20200414]--[@b8-1600-1-12698-1-10-20200414]\]^.

Our patient had not started any prescribed or over-the-counter medication, other than lisinopril, during the year before admission. Therefore, the derangement in LFT due to cholestasis was most probably caused by lisinopril. It is unlikely that the patient's other regular medications, especially gliclazide and atorvastatin, would have precipitated cholestasis. First-generation sulfonylureas are associated with cholestatic liver injury, but gliclazide is a second-generation sulfonylurea. Three case reports have described gliclazide-induced acute hepatitis, but all within 3 months of commencing the drug, and patients seemed to improve after discontinuing the medication^\[[@b9-1600-1-12698-1-10-20200414]\]^.

Previous studies revealed evidence of atorvastatin hepatotoxicity in the form of mildly raised ALT. Severe hepatotoxicity is a very rare side effect of atorvastatin. Severe hepatotoxicity secondary to atorvastatin usually manifests as mixed cholestatic/hepatocellular injury. The time between drug exposure and presumed atorvastatin-induced liver injury was 3 months or less in a number of cases reported in the English literature^\[[@b10-1600-1-12698-1-10-20200414]\]^.

CONCLUSION
==========

We report a second case of lisinopril liver injury, with a cholestatic liver enzyme pattern, which unfortunately did not resolve.
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###### 

Summary of the presented case and previously published cases of lisinopril-induced liver injury

  Country, (year)      Age       Sex   Time to, symptoms   Symptoms                               Consequences                                                                     Pattern of liver, damage   Liver biopsy                                                                                                                                 References
  -------------------- --------- ----- ------------------- -------------------------------------- -------------------------------------------------------------------------------- -------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------
  France (1990)        66        M     2 weeks             Jaundice, fever, myalgia               Hepatic encephalopathy,ascites, perforated DU, bacterial peritonitis and death   Hepatocellular             Centrilobular necrosis, cholestasis, polymorphic and monocytic inflammatory infiltrate                                                       Larrey et al. ^\[[@b4-1600-1-12698-1-10-20200414]\]^
  USA (1993)           Unknown   M     Unknown             Unknown                                Survived, LFT normalised                                                         Hepatocellular             Toxic injury without cholestasis                                                                                                             Hilburn et al. \[[@b5-1600-1-12698-1-10-20200414]\]
  UK (1995)            64        F     12 days             Jaundice                               Aplastic anaemia, sepsis, died                                                   Hepatocellular             Bone marrow aplasia with changes indicating hepatorenal failure on post-mortem examination                                                   Harrison et al. \[[@b6-1600-1-12698-1-10-20200414]\]
  Netherlands (1995)   56        M     4 months            Jaundice, fatigue, pruritus            Chronic liver disease                                                            Hepatocellular             Fibrosed portal tract with markedly prominent ductular proliferation. Plasma cells and granulocytes infiltration. Intrahepatic cholestasis   Droste et al. \[[@b7-1600-1-12698-1-10-20200414]\]
  USA (2010)           30        F     8 months            Fatigue and jaundice                   Survived, LFT normalised                                                         Hepatocellular             Interface hepatitis, lymphocytic portal infiltration                                                                                         Zalawadiya et al. \[[@b8-1600-1-12698-1-10-20200414]\]
  Jamaica (2014)       47        F     2 years             Weakness, jaundice, loss of appetite   Survived, LFT normalised                                                         Cholestatic                Portal fibrosis and inflammation, cholestasis, lymphocytic cell infiltration                                                                 Singh et al. \[[@b1-1600-1-12698-1-10-20200414]\]
  UK (2017)            59        F     8 weeks             Jaundice                               LFT did not resolve, died                                                        Cholestatic                Acute cholestasis with canalicular bile plugs; with focal portal-to-portal bridging fibrosis and centrilobular steatosis                     Our case
  Median               57              12 weeks                                                                                                                                                                                                                                                                                                            

DU, duodenal ulcer; LFT, liver function test.
